Headache News and Research

Latest Headache News and Research

Mich. physicians group seeks standing in Kan. abortion case; Mass. anti-abortion group pushes to overturn health law

The American Association of Pro-Life Obstetricians and Gynecologists is seeking to appeal a federal court ruling that temporarily blocked the Kansas law, the Kansas City Star reports. Meanwhile, the effort by abortion opponents in Massachusetts could be a complication for presidential candidate Mitt Romney.

4 Aug 2011

'Concussions in the Classroom' program for high school teachers

According to a recent study by the American Academy of Pediatrics, concussions among middle and high school students are skyrocketing sending more than 100,000 adolescents and children a year to the emergency room.

4 Aug 2011

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

MAP Pharmaceuticals, Inc. today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA).

2 Aug 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Viewpoints: Sanders on angry Americans; Sebelius on Md. exchanges; Samuelson: 'it's the elderly, stupid'

If the Republicans have their way, the entire burden of deficit reduction will be placed on the elderly, the sick, children and working families. In the midst of a horrendous recession that is already causing severe pain for average Americans, this approach is morally grotesque. ... The Reid plan is bad. The constantly shifting plan by House Speaker John Boehner is much worse. ... Those cuts would mean drastic reductions in Social Security, Medicare and Medicaid.

30 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

Stroke in pregnancy on the rise

According to latest reports the number of strokes among pregnant women and new mothers has risen to a new peak probably because more of them are obese and suffering from high blood pressure and heart disease.

29 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Mayo Clinic releases recommendations from the ice hockey concussion summit

Mayo Clinic has released recommendations from the Ice Hockey Summit on Concussion: A Call to Action. The summit attracted top scientists, trainers, coaches, officials and equipment manufacturers from across the United States, Canada and Europe to discuss concussion-related issues, including the science of concussions, impact on children, and prevention.

27 Jul 2011

Patients with MTBI exhibit abnormal functional connectivity in the thalamus

A new study has found that patients with mild traumatic brain injury (MTBI) exhibit abnormal functional connectivity in the thalamus, a centrally located relay station for transmitting information throughout the brain.

26 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Exchanges: HHS official offers insights on state deadline, insurer roles

During a news briefing in Washington, D.C., Steve Larsen, deputy administrator and director of the Center for Consumer Information and Insurance Oversight at the CMS, discussed certain issues related to the establishment of state health exchanges.

22 Jul 2011

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Headache News and Research

Latest Headache News and Research

Mich. physicians group seeks standing in Kan. abortion case; Mass. anti-abortion group pushes to overturn health law

'Concussions in the Classroom' program for high school teachers

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Viewpoints: Sanders on angry Americans; Sebelius on Md. exchanges; Samuelson: 'it's the elderly, stupid'

Cadence confirms FDA dosing recommendations for OFIRMEV

Stroke in pregnancy on the rise

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

POZEN reports revenue of $4.6 million for second quarter 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Mayo Clinic releases recommendations from the ice hockey concussion summit

Patients with MTBI exhibit abnormal functional connectivity in the thalamus

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Exchanges: HHS official offers insights on state deadline, insurer roles

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in